Zevra Denmark As Patent-Cliff Exposure & CMS Drug Spending Portfolio

Zevra Denmark As (US): 1 reconciled FDA prescription therapies, $3.1M 2024 CMS Part D & Medicaid spend, and $106,020 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies1
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2041-01-01
2024 CMS Total Public Spend$3.1M
2024 Medicare Part D Spend$1.9M
2024 Medicaid Spend$1.2M
California HCAI SB 17 FilingsSpecialty launch notice ($106,020 intro WAC)